These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Toxicity of the CYVADIC modification in patients with soft tissue sarcomas or malignant mesotheliomas]. Sauer H; Kremer G; Wilmanns W Onkologie; 1987 Oct; 10(5):294-300. PubMed ID: 3317170 [TBL] [Abstract][Full Text] [Related]
10. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Lindén CJ; Mercke C; Albrechtsson U; Johansson L; Ewers SB Eur Respir J; 1996 Dec; 9(12):2565-72. PubMed ID: 8980970 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. Samson MK; Wasser LP; Borden EC; Wanebo HJ; Creech RH; Phillips M; Baker LH J Clin Oncol; 1987 Jan; 5(1):86-91. PubMed ID: 3543239 [TBL] [Abstract][Full Text] [Related]
12. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326 [TBL] [Abstract][Full Text] [Related]
13. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Kasseyet S; Astoul P; Boutin C Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568 [TBL] [Abstract][Full Text] [Related]
14. The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma. Yap BS; Benjamin RS; Burgess MA; Bodey GP Cancer; 1978 Oct; 42(4):1692-6. PubMed ID: 709531 [TBL] [Abstract][Full Text] [Related]
15. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Anand A; Anand A; Anand N Cancer; 1996 May; 77(9):1959-60. PubMed ID: 8646700 [No Abstract] [Full Text] [Related]
16. [Morphological characteristics of experimental peritoneal and pleural mesotheliomas caused by crocidolite asbestos]. Kolev K; Topov Ia Gig Tr Prof Zabol; 1984 Jan; (1):31-4. PubMed ID: 6321301 [No Abstract] [Full Text] [Related]
17. [Chemotherapy of operated diffuse malignant mesotheliomas. Trials and preliminary results]. Mannes P; Renault P; Derriks R; Mannes R Lille Med; 1978 Jan; 23(1):36-40. PubMed ID: 634033 [No Abstract] [Full Text] [Related]
18. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Law MR; Gregor A; Hodson ME; Bloom HJ; Turner-Warwick M Thorax; 1984 Apr; 39(4):255-9. PubMed ID: 6426072 [TBL] [Abstract][Full Text] [Related]
19. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of 15 malignant mesothelioma patients from the aspect of clinical findings and pathology--relationship between asbestos and malignant mesothelioma]. Kishimoto T; Ono T; Okada K Nihon Naika Gakkai Zasshi; 1987 Apr; 76(4):586-7. PubMed ID: 3611919 [No Abstract] [Full Text] [Related] [Next] [New Search]